The saphnelo market research report is one of a series of new reports that provides saphnelo market statistics, including the saphnelo industry global market size, regional shares, competitors with the saphnelo market share, detailed saphnelo market segments, market trends, and opportunities, and any further data you may need to thrive in the saphnelo industry. This saphnelo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to growing awareness and diagnosis, increase investment in biopharmaceuticals, expansion of patient assistance programs, growing educational initiatives around lupus and advanced therapies, and growing demand for personalized medicine. Major trends in the forecast period include integration of AI in R&D, innovation in drug delivery systems, biologic manufacturing advances, focus on sustainable manufacturing practices, and telehealth integration for treatment monitoring.
The increasing prevalence of autoimmune diseases is expected to drive the growth of the Saphnelo market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues, viewing them as harmful invaders. This rise is linked to factors such as genetic predisposition, environmental influences, lifestyle changes, and greater awareness. Saphnelo (anifrolumab) helps manage these conditions by targeting and blocking the type I interferon receptor, a key immune system component often overactive in autoimmune diseases. By reducing inflammation and disease activity, it helps improve patient outcomes. For example, a systematic review in 2022, published by the National Library of Medicine, examined 464 studies and found 928 cases of autoimmune diseases linked to COVID-19 vaccination. Of these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms typically appearing about eight days after vaccination. The majority of affected individuals were women, with a median age of 48. Thus, the growing incidence of autoimmune diseases is driving the demand for Saphnelo.
The growth of healthcare infrastructure is also expected to contribute to the expansion of the Saphnelo market. Healthcare infrastructure refers to the physical facilities, systems, and resources necessary for effective healthcare delivery. This expansion is largely driven by an aging population, population growth, and the increasing prevalence of chronic diseases, all of which heighten the demand for medical services. An improved healthcare infrastructure can boost access to advanced treatments such as Saphnelo, facilitating wider distribution and better availability for patients in need. For example, the United States saw an increase in hospitals, with 6,120 hospitals in 2024, up from 6,093 in 2022, according to the American Hospital Association. This expansion supports the growing demand for treatments such as Saphnelo.
A significant trend in the Saphnelo market is the regulatory approval of new antibody therapies for autoimmune diseases. Regulatory approval allows drugs, medical devices, or treatments to be marketed and used by the public, confirming their safety and efficacy. In February 2022, AstraZeneca received approval from the European Union for Saphnelo. This first-in-class type I interferon receptor antibody is used as an add-on therapy for moderate to severe systemic lupus erythematosus (SLE), aiming to reduce disease activity and reliance on oral corticosteroids. The approval was based on clinical data from the TULIP Phase III and MUSE Phase II trials, which showed that more patients treated with Saphnelo experienced a significant reduction in disease activity across multiple organ systems and a sustained reduction in corticosteroid use compared to those on a placebo.
The key company operating in the saphnelo market is AstraZeneca PLC.
North America was the largest region in the saphnelo market in 2024. The regions covered in saphnelo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the saphnelo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Saphnelo is a monoclonal antibody drug used to treat moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. It works by targeting and inhibiting the interferon receptor, which is involved in the inflammatory process of lupus. By blocking the interferon pathway, Saphnelo helps reduce inflammation and immune system activity, improving symptoms and reducing flare-ups in lupus patients.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Saphnelo include systemic lupus erythematosus, lupus nephritis, cutaneous lupus, systemic sclerosis, and myositis. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that leads to inflammation and damage to multiple organs due to immune dysregulation and the production of autoantibodies. Saphnelo is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a variety of end users, such as hospitals, clinics, ambulatory care settings, and home care environments.
The saphnelo market consists of sales of immunomodulators, immunosuppressants, corticosteroids and immunotherapy treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing awareness and diagnosis, increase investment in biopharmaceuticals, expansion of patient assistance programs, growing educational initiatives around lupus and advanced therapies, and growing demand for personalized medicine. Major trends in the forecast period include integration of AI in R&D, innovation in drug delivery systems, biologic manufacturing advances, focus on sustainable manufacturing practices, and telehealth integration for treatment monitoring.
The increasing prevalence of autoimmune diseases is expected to drive the growth of the Saphnelo market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues, viewing them as harmful invaders. This rise is linked to factors such as genetic predisposition, environmental influences, lifestyle changes, and greater awareness. Saphnelo (anifrolumab) helps manage these conditions by targeting and blocking the type I interferon receptor, a key immune system component often overactive in autoimmune diseases. By reducing inflammation and disease activity, it helps improve patient outcomes. For example, a systematic review in 2022, published by the National Library of Medicine, examined 464 studies and found 928 cases of autoimmune diseases linked to COVID-19 vaccination. Of these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms typically appearing about eight days after vaccination. The majority of affected individuals were women, with a median age of 48. Thus, the growing incidence of autoimmune diseases is driving the demand for Saphnelo.
The growth of healthcare infrastructure is also expected to contribute to the expansion of the Saphnelo market. Healthcare infrastructure refers to the physical facilities, systems, and resources necessary for effective healthcare delivery. This expansion is largely driven by an aging population, population growth, and the increasing prevalence of chronic diseases, all of which heighten the demand for medical services. An improved healthcare infrastructure can boost access to advanced treatments such as Saphnelo, facilitating wider distribution and better availability for patients in need. For example, the United States saw an increase in hospitals, with 6,120 hospitals in 2024, up from 6,093 in 2022, according to the American Hospital Association. This expansion supports the growing demand for treatments such as Saphnelo.
A significant trend in the Saphnelo market is the regulatory approval of new antibody therapies for autoimmune diseases. Regulatory approval allows drugs, medical devices, or treatments to be marketed and used by the public, confirming their safety and efficacy. In February 2022, AstraZeneca received approval from the European Union for Saphnelo. This first-in-class type I interferon receptor antibody is used as an add-on therapy for moderate to severe systemic lupus erythematosus (SLE), aiming to reduce disease activity and reliance on oral corticosteroids. The approval was based on clinical data from the TULIP Phase III and MUSE Phase II trials, which showed that more patients treated with Saphnelo experienced a significant reduction in disease activity across multiple organ systems and a sustained reduction in corticosteroid use compared to those on a placebo.
The key company operating in the saphnelo market is AstraZeneca PLC.
North America was the largest region in the saphnelo market in 2024. The regions covered in saphnelo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the saphnelo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Saphnelo is a monoclonal antibody drug used to treat moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. It works by targeting and inhibiting the interferon receptor, which is involved in the inflammatory process of lupus. By blocking the interferon pathway, Saphnelo helps reduce inflammation and immune system activity, improving symptoms and reducing flare-ups in lupus patients.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Saphnelo include systemic lupus erythematosus, lupus nephritis, cutaneous lupus, systemic sclerosis, and myositis. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that leads to inflammation and damage to multiple organs due to immune dysregulation and the production of autoantibodies. Saphnelo is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a variety of end users, such as hospitals, clinics, ambulatory care settings, and home care environments.
The saphnelo market consists of sales of immunomodulators, immunosuppressants, corticosteroids and immunotherapy treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Saphnelo Market Characteristics4. Saphnelo Market Trends And Strategies5. Saphnelo Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Saphnelo Pricing Analysis & Forecasts30. Global Saphnelo Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Saphnelo Market32. Recent Developments In The Saphnelo Market
3. Saphnelo Market Biologic Drug Characteristics
6. Global Saphnelo Growth Analysis And Strategic Analysis Framework
8. Saphnelo Market Segmentation
9. Global Saphnelo Epidemiology Of Clinical Indications
10. Saphnelo Market Regional And Country Analysis
11. Asia-Pacific Saphnelo Market
12. China Saphnelo Market
13. India Saphnelo Market
14. Japan Saphnelo Market
15. Australia Saphnelo Market
16. South Korea Saphnelo Market
17. Western Europe Saphnelo Market
18. UK Saphnelo Market
19. Germany Saphnelo Market
20. France Saphnelo Market
21. Eastern Europe Saphnelo Market
22. North America Saphnelo Market
23. USA Saphnelo Market
24. Canada Saphnelo Market
25. South America Saphnelo Market
26. Middle East Saphnelo Market
27. Africa Saphnelo Market
28. Saphnelo Market Competitive Landscape And Company Profiles
29. Global Saphnelo Market Pipeline Analysis
33. Saphnelo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Saphnelo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on saphnelo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for saphnelo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The saphnelo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Systemic Lupus Erythematosus; Lupus Nephritis; Cutaneous Lupus; Systemic Sclerosis; Myositis2) By Distribution Channe: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: AstraZeneca PLC.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- AstraZeneca PLC.